Source: Circulation-cardiovascular quality and outcomes. Unidade: FM
Subjects: ENZIMAS PROTEOLÍTICAS, ISQUEMIA MIOCÁRDICA, INFARTO DO MIOCÁRDIO, HOSPITALIZAÇÃO
ABNT
SZAREK, Michael et al. Alirocumab reduces total hospitalizations and increases days alive and out of Hospital in the ODYSSEY OUTCOMES Trial. Circulation-cardiovascular quality and outcomes, v. 12, n. 11, 2019Tradução . . Disponível em: https://doi.org/10.1161/CIRCOUTCOMES.119.005858. Acesso em: 12 jun. 2024.APA
Szarek, M., Steg, P. G., Dicenso, D., Bhatt, D. L., Bittner, V. A., Budaj, A., et al. (2019). Alirocumab reduces total hospitalizations and increases days alive and out of Hospital in the ODYSSEY OUTCOMES Trial. Circulation-cardiovascular quality and outcomes, 12( 11). doi:10.1161/CIRCOUTCOMES.119.005858NLM
Szarek M, Steg PG, Dicenso D, Bhatt DL, Bittner VA, Budaj A, Diaz R, Goodman SG, Gotcheva N, Nicolau JC. Alirocumab reduces total hospitalizations and increases days alive and out of Hospital in the ODYSSEY OUTCOMES Trial [Internet]. Circulation-cardiovascular quality and outcomes. 2019 ; 12( 11):[citado 2024 jun. 12 ] Available from: https://doi.org/10.1161/CIRCOUTCOMES.119.005858Vancouver
Szarek M, Steg PG, Dicenso D, Bhatt DL, Bittner VA, Budaj A, Diaz R, Goodman SG, Gotcheva N, Nicolau JC. Alirocumab reduces total hospitalizations and increases days alive and out of Hospital in the ODYSSEY OUTCOMES Trial [Internet]. Circulation-cardiovascular quality and outcomes. 2019 ; 12( 11):[citado 2024 jun. 12 ] Available from: https://doi.org/10.1161/CIRCOUTCOMES.119.005858